EUVIMEDEUVIMED entdecken
Crossref

Persistent underuse of extended venous thromboembolism prophylaxis in patients undergoing major abdominal cancer operations

Joshua N Herb, Yoshiko Iwai, Lisette N Dunham, Karyn B Stitzenberg

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Joshua N Herb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guidelines recommend extended venous thromboembolism (VTE) prophylaxis for high‐risk populations undergoing major abdominal cancer operations. Few studies have evaluated extended VTE prophylaxis in the Medicare population who are at higher risk due to age.

Methods

We performed a retrospective study using a 20% random sample of Medicare claims, 2012–2017. Patients ≥65 years with an abdominal cancer undergoing resection were included. Primary outcome was the proportion of patients receiving new extended VTE prophylaxis prescriptions at discharge. Secondary outcomes included postdischarge VTE and hemorrhagic events.

Results

The study included 72 983 patients with a mean age of 75. Overall, 8.9% of patients received extended VTE prophylaxis. This proportion increased (7.2% in 2012, 10.6% in 2017; p < 0.001). Incidence of postdischarge hemorrhagic events was 1.0% in patients receiving extended VTE prophylaxis and 0.8% in those who did not. The incidence of postdischarge VTE events was 5.2% in patients receiving extended VTE prophylaxis and 2.4% in those who did not.

Conclusion

Adherence to guideline‐recommended extended VTE prophylaxis in high‐risk patients undergoing major abdominal cancer operations is low. The higher rate of VTE in the prophylaxis group may suggest we captured some therapeutic anticoagulation, which would mean the actual rate of thromboprophylaxis is lower than reported herein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsHumansAgedUnited StatesAnticoagulantsRetrospective StudiesAftercarePatient DischargeMedicareRisk FactorsHemorrhagePrescriptions

Stichwörter der Autor:innen

VTE prophylaxisabdominal cancerextended VTE prophylaxismajor abdominal cancerthromboprophylaxis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Clinical Decision Support, Mass General Brigham eCare, Boston, Massachusetts, USA.
  • Division of Surgical Oncology, Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Zitieren

APA

Herb, J. N., Iwai, Y., Dunham, L. N., & Stitzenberg, K. B. (2024). Persistent underuse of extended venous thromboembolism prophylaxis in patients undergoing major abdominal cancer operations. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27473

Vancouver

Herb JN, Iwai Y, Dunham LN, Stitzenberg KB. Persistent underuse of extended venous thromboembolism prophylaxis in patients undergoing major abdominal cancer operations. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27473

BibTeX
@article{Herb2024,
  author = {Herb, Joshua N and Iwai, Yoshiko and Dunham, Lisette N and Stitzenberg, Karyn B},
  title = {Persistent underuse of extended venous thromboembolism prophylaxis in patients undergoing major abdominal cancer operations},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27473}
}
Kostenlos starten →